Friday, December 03, 2010 12:50:14 PM
Only 3 followers on this forum?
A beautiful value for the speculation in the past... now becoming a strong value with very high growth potential for the next months.
My personnl target is 0,7 by the end of the year.
With all the good news accumulating, it is still possible.
What do you think?
A beautiful value for the speculation in the past... now becoming a strong value with very high growth potential for the next months.
My personnl target is 0,7 by the end of the year.
With all the good news accumulating, it is still possible.
What do you think?
Recent PHARM News
- Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older • GlobeNewswire Inc. • 03/27/2026 06:00:00 AM
- Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older • GlobeNewswire Inc. • 03/24/2026 06:00:00 AM
- Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow • GlobeNewswire Inc. • 03/12/2026 06:00:00 AM
- Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day • GlobeNewswire Inc. • 02/03/2026 06:00:00 AM
- Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS • GlobeNewswire Inc. • 02/01/2026 08:17:00 PM
- DAX, CAC, FTSE100, European equities drift lower amid U.S.–Venezuela tensions and data watch • UK Market News • 01/08/2026 02:17:15 PM
- Pharming Group reports preliminary 2025 revenues and announces Investor Day • GlobeNewswire Inc. • 01/08/2026 06:00:00 AM
- Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow • GlobeNewswire Inc. • 11/06/2025 06:00:00 AM
- Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio • GlobeNewswire Inc. • 10/20/2025 06:00:33 AM
- Pharming Group provides update on previously announced G&A expense reduction plan • GlobeNewswire Inc. • 10/06/2025 03:35:57 PM
- Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years • GlobeNewswire Inc. • 10/01/2025 05:00:25 AM
- Pharming Group promoted to the Euronext AMX® index • GlobeNewswire Inc. • 09/10/2025 05:00:00 AM
- Pharming Group appoints Kenneth Lynard as Chief Financial Officer • GlobeNewswire Inc. • 09/02/2025 05:00:00 AM
- Pharming Group reports second quarter and first half 2025 financial results and provides business update • GlobeNewswire Inc. • 07/31/2025 05:00:00 AM
- Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis • GlobeNewswire Inc. • 06/24/2025 05:00:00 AM
- Pharming Group reports first quarter 2025 financial results and provides business update • GlobeNewswire Inc. • 05/08/2025 05:00:00 AM
- Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) • GlobeNewswire Inc. • 04/25/2025 01:00:00 PM
- Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS • GlobeNewswire Inc. • 04/23/2025 07:30:00 AM
